How should C‑peptide be measured and interpreted in a patient receiving exogenous insulin therapy?

C-Peptide Measurement in Patients Receiving Exogenous Insulin

C-peptide remains a valid and clinically useful marker of endogenous insulin secretion even in patients receiving exogenous insulin therapy, as exogenous insulin does not cross-react with C-peptide assays and C-peptide is secreted in equimolar amounts with endogenous insulin only. 1, 2

Key Principle: Exogenous Insulin Does Not Interfere with C-Peptide Measurement

• C-peptide has no biological activity but is produced in equal amounts to endogenous insulin during proinsulin processing. 1, 3
• Exogenous insulin administration does not directly affect C-peptide levels, as C-peptide assays do not detect administered insulin. 1, 2
• C-peptide measurement provides superior diagnostic value compared to insulin levels because it is not cleared by the liver and has a more constant excretion rate over a longer time period. 1, 4

Critical Diagnostic Pattern: Insulin vs. C-Peptide Interpretation

When Insulin is High but C-Peptide is Low (<0.6 ng/mL):

• Insulin levels greatly exceeding 3 mIU/L with C-peptide <0.6 ng/mL indicates exogenous insulin administration. 1
• This pattern is diagnostic for factitious hypoglycemia from injected insulin. 1
• Important caveat: Some insulin analogues (lispro, aspart, glargine) may not be recognized on certain insulin assays, potentially showing low insulin levels despite exogenous administration—this presentation mimics non-insulin hypoglycemia. 1

When Both Insulin and C-Peptide are Elevated (≥3 mIU/L and ≥0.6 ng/mL):

• This pattern indicates endogenous hyperinsulinism (insulinoma or nesidioblastosis). 1
• Differential diagnosis includes occult sulfonylurea/meglitinide use or anti-insulin antibodies. 1

Measurement Thresholds and Interpretation

Standard C-Peptide Thresholds:

• C-peptide <0.2 nmol/L (approximately <0.6 ng/mL) suggests type 1 diabetes with severe insulin deficiency. 2, 5, 6
• C-peptide ≥0.6 ng/mL (≥0.2 nmol/L) for hypoglycemia ≤45 mg/dL (2.5 mmol/L) has almost 100% sensitivity and specificity for diagnosing inappropriate endogenous insulin secretion. 1
• C-peptide >0.6 nmol/L indicates type 2 diabetes or preserved beta-cell function. 5, 6

Conversion Factor:

• pmol/L is converted to ng/mL by multiplying by 0.003. 1

Clinical Applications in Insulin-Treated Patients

Distinguishing Type 1 from Type 2 Diabetes:

• C-peptide measurement (fasting or glucagon-stimulated) helps differentiate type 1 from type 2 diabetes in ambiguous cases, such as individuals with type 2 phenotype presenting in ketoacidosis. 5
• Utility is greatest 3-5 years after diagnosis when persistence of substantial insulin secretion suggests type 2 or monogenic diabetes rather than type 1. 3
• Absent C-peptide at any time confirms absolute insulin requirement regardless of apparent etiology. 3

Investigating Hypoglycemia:

• C-peptide measurement is essential in investigating non-diabetic hypoglycemia to rule out surreptitious insulin administration. 5
• Samples should be obtained during documented hypoglycemia (plasma glucose <55 mg/dL or 3.0 mmol/L). 2

Predicting Insulin Dependency:

• Measuring C-peptide after glucagon stimulation is a discriminative method to establish insulin dependency in obese diabetic patients treated with insulin. 7
• A negative C-peptide response (minimal increase of 0-0.1 ng/mL after glucagon) indicates true insulin dependency (type 1 diabetes). 7

Important Methodological Considerations

Timing of Measurement:

• For insurance coverage of insulin pump therapy, measure fasting C-peptide when simultaneous fasting plasma glucose is ≤220 mg/dL (12.5 mmol/L). 5
• Random non-fasting C-peptide is convenient and performs well compared to gold standard testing for classification of severe insulin deficiency. 8
• C-peptide at 2 hours post-meal may be a better predictor than fasting C-peptide for assessing endogenous insulin secretory capacity. 9

Effect of Glycemic Control:

• Blood glucose reduction, rather than exogenous insulin itself, is responsible for C-peptide decrease during insulin therapy in type 2 diabetic patients. 10
• Research shows that fasting C-peptide levels were lower during insulin therapy compared to pre-treatment, but this difference disappeared when C-peptide/glucose ratio was compared. 10

Special Populations Where Standard Thresholds May Not Apply:

• Renal insufficiency: Standard thresholds are non-applicable; use plasma beta-hydroxybutyrate assay and glucagon stimulation test instead. 1
• Hepatic insufficiency: Thresholds have not been validated. 1
• Post-partial pancreatectomy: Thresholds have not been validated. 1
• Certain genetic forms of nesidioblastosis: May show inappropriate insulin secretion with suppressed C-peptide at lower glucose thresholds. 1

Critical Pitfalls to Avoid

Assay Variability:

• Significant variability exists between different C-peptide assay manufacturers despite ongoing standardization efforts. 6
• Thresholds should be validated by your own laboratory using specific assay methods and kits. 1
• Immunochemiluminometric assay (ICMA) is commonly used, such as the ADVIA Centaur kit. 1

Sepsis and Critical Illness:

• Sepsis increases C-peptide levels and uncouples serum C-peptide and insulin levels in critically ill patients with type 2 diabetes. 11
• In septic patients not receiving exogenous insulin, C-peptide levels are elevated with a threefold higher C-peptide to insulin ratio compared to non-septic patients. 11
• Exogenous insulin administration in septic patients decreases both C-peptide levels and C-peptide to insulin ratios. 11

Insulin Antibodies:

• Anti-insulin antibodies can cause elevated insulin levels with elevated C-peptide, mimicking endogenous hyperinsulinism. 1
• Always measure insulin antibodies when evaluating hypoglycemia. 2